Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: Case report and review of literature

Lung Cancer

Volumn 44, Issue 3, 2004, Pages 381-390

  D'Amato, Gina ^a,b   Lima, Caio Rocha ^c   Mahany, J J ^a,b   Muro Cacho, Carlos ^b   Haura, Eric B ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Chemotherapy; Lung cancer; Neutropenic enterocolitis; Taxanes; Typhlitis

Indexed keywords

CARBOPLATIN; DOCETAXEL; FLAVOPIRIDOL; PACLITAXEL; TAXANE DERIVATIVE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADENOSQUAMOUS CARCINOMA; AGED; ANAMNESIS; AREA UNDER THE CURVE; AUTOPSY; BRAIN INJURY; CASE REPORT; CLINICAL TRIAL; CONFUSION; DIAGNOSTIC PROCEDURE; DIARRHEA; ENTEROCOLITIS; FATIGUE; FEMALE; FEVER; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; LABORATORY TEST; LUNG ADENOCARCINOMA; LUNG INJURY; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; NEUROPATHY; NEUTROPENIA; NEUTROPENIC ENTEROCOLITIS; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; SEPTICEMIA; SHOCK;

EID: 2342452448     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.11.018     Document Type: Article

References (48)

1. Slavin R.E., Dias M.A., Saral R. Cytosine arabinoside-induced gastro-intestinal toxic alterations in sequential chemotherapeutic protocols: a clinical-pathologic study of 33 patients. Cancer. 42(4):1978;1747-1759
2. Vlasveld L.T., Zwaan F.E., Fibbe W.E., Tjon R.T., Tham T.A., Kluin P.M., et al. Neutropenic enterocolitis following treatment with cytosine arabinoside-containing regimens for hematological malignancies: a potentiating role for amsacrine. Ann. Hematol. 62(4):1991;129-134
3. Kulaylat M., Doerr R., Ambrus J. A case presentation and review of neutropenic enterocolitis. J. Med. 28(1-2):1997;1-19
4. Song H.K., Kreisel D., Canter R., Krupnick A.S., Stadtmauer E.A., Buzby G. Changing presentation and management of neutropenic enterocolitis. Arch. Surg. 133(9):1998;979-982
5. Stemmler H.J., Kenngotte S., Diepolder H., Heinemann V. Gastro-intestinal toxicity associated with weekly docetaxel treatment. Ann. Oncol. 13(6):2002;978-981
6. Cardenal F., Montes A., Llort G., Segui J., Mesia R. Typhlitis associated with docetaxel treatment. J. Natl. Cancer Inst. 88(15):1996;1078-1079
7. Millward M.J., Zalcberg J., Bishop J.F., Webster L.K., Zimet A., Rischin D., et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 15(2):1997;750-758
8. Kourousis C., Androulakis N., Kakolyris S., Souglakos J., Maltezakis G., Metaxaris G., et al. First-line treatment of advanced non-non-small-cell lung carcinoma with docetaxel and vinorelbine. Cancer. 83(10):1998;2083-2090
9. Bavaro M.F. Neutropenic enterocolitis. Curr. Gastroenterol. Rep. 4(4):2002;297-301
10. Hogan W.J., Letendre L., Litzow M.R., Tefferi A., Hoagland H.C., Pruthi R.K., et al. Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. Mayo Clin. Proc. 77(8):2002;760-762
11. Abbasoglu O., Cakmakci M. Neutropenic enterocolitis in patients without leukemia. Surgery. 113(1):1993;113-116
12. Mower W.J., Hawkins J.A., Nelson E.W. Neutropenic enterocolitis in adults with acute leukemia. Arch. Surg. 121(5):1986;571-574
13. Williams N., Scott A.D. Neutropenic colitis: a continuing surgical challenge. Br. J. Surg. 84(9):1997;1200-1205
14. Wagner M.L., Rosenberg H.S., Fernbach D.J., Singleton E.B. Typhlitis: a complication of leukemia in childhood. Am. J. Roentgenol. Radium. Ther. Nucl. Med. 109(2):1970;341-350
15. Sherman N.J., Woolley M.M. The ileocecal syndrome in acute childhood leukemia. Arch. Surg. 107(1):1973;39-42
16. Dosik G.M., Luna M., Valdivieso M., McCredie K.B., Gehan E.A., Gil-Extremera B., et al. Necrotizing colitis in patients with cancer. Am. J. Med. 67(4):1979;646-656
17. Shamberger R.C., Weinstein H.J., Delorey M.J., Levey R.H. The medical and surgical management of typhlitis in children with acute non-lymphocytic (myelogenous) leukemia. Cancer. 57(3):1986;603-609
18. D'Souza S., Lindberg M. Typhlitis as a presenting manifestation of acute myelogenous leukemia. South Med. J. 93(2):2000;218-220
19. Pagani O., Sessa C., Martinelli G., Crivellari D., Buonadonna A., Thurlimann B., et al. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann. Oncol. 10(5):1999;539-545
20. Ibrahim N.K., Rahman Z., Valero V., Murray J.L. III, Frye D., Hortobagyi G.N. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. Cancer Invest. 20(1):2002;29-37
21. Ibrahim N.K., Sahin A.A., Dubrow R.A., Lynch P.M., Boehnke-Michaud L., Valero V., et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 355(9200):2000;281-283
22. Hayes D. Jr., Leonardo J.M. Neutropenic enterocolitis in a woman treated with 5-fluorouracil and leucovorin for colon carcinoma. N. C. Med. J. 63(3):2002;132-134
23. Polee M.B., Verweij J., Siersema P.D., Tilanus H.W., Splinter T.A., Stoter G., et al. Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer. Eur. J. Cancer. 38(11):2002;1495-1500
24. Petrylak D.P., Macarthur R.B., O'Connor J., Shelton G., Judge T., Balog J., et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J. Clin. Oncol. 17(3):1999;958-967
25. Kreis W., Petrylak D., Savarese D., Budman D. Colitis and docetaxel-based chemotherapy. Lancet. 355(9221):2000;2164
26. Urbach D.R., Rotstein O.D. Typhlitis. Can. J. Surg. 42(6):1999;415-419
27. Ettinghausen S.E. Collagenous colitis, eosinophilic colitis, and neutropenic colitis. Surg. Clin. North Am. 73(5):1993;993-1016
28. Wade D.S., Nava H.R., Douglass H.O. Jr. Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer. 69(1):1992;17-23
29. Ikard R.W. Neutropenic typhlitis in adults. Arch. Surg. 116(7):1981;943-945
30. Katz J.A., Wagner M.L., Gresik M.V., Mahoney D.H. Jr., Fernbach D.J. Typhlitis. An 18-year experience and postmortem review. Cancer. 65(4):1990;1041-1047
31. Hiruki T., Fernandes B., Ramsay J., Rother I. Acute typhlitis in an immuno-compromised host. Report of an unusual case and review of the literature. Dig. Dis. Sci. 37(8):1992;1292-1296
32. Sloas M.M., Flynn P.M., Kaste S.C., Patrick C.C. Typhlitis in children with cancer: a 30-year experience. Clin. Infect. Dis. 17(3):1993;484-490
33. Pokorney B.H., Jones J.M., Shaikh B.S., Aber R.C. Typhlitis. A treatable cause of recurrent septicemia. JAMA. 243(7):1980;682-683
34. Cartoni C., Dragoni F., Micozzi A., Pescarmona E., Mecarocci S., Chirletti P., et al. Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography. J. Clin. Oncol. 19(3):2001;756-761
35. Moir C.R., Scudamore C.H., Benny W.B. Typhlitis: selective surgical management. Am. J. Surg. 151(5):1986;563-566
36. Fossella F., Pereira J.R., Von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non-Small-Cell Lung Cancer: The TAX 326 Study Group. J. Clin. Oncol. 21(16):2003;3016-3024
37. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small-cell Lung Cancer Study Group. J. Clin. Oncol. 18(12):2000;2354-2362
38. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2):2002;92-98
39. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18(10):2000;2095-2103
40. Tan A.R., Headlee D., Messmann R., Sausville E.A., Arbuck S.G., Murgo A.J., et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1 h infusion in patients with advanced neoplasms. J. Clin. Oncol. 20(19):2002;4074-4082
41. Kouroukis C.T., Belch A., Crump M., Eisenhauer E., Gascoyne R.D., Meyer R., et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21(9):2003;1740-1745
42. Shapiro G.I., Supko J.G., Patterson A., Lynch C., Lucca J., Zacarola P.F., et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-non-small-cell lung cancer. Clin. Cancer Res. 7(6):2001;1590-1599
43. Gamboa-Dominguez A., Velazquez-Cecena J.L., Reyes-Gutierrez E. Neutropenic enteropathy associated with multiple myeloma. Rev. Gastroenterol. Mex. 60(2):1995;94-97
44. Uzuka Y., Saito Y., Takahashi H., Komatu M., Ito T. Neutropenic enterocolitis in adults with acute leukemia. Rinsho Ketsueki. 30(7):1989;980-987
45. Kelly K.M., Hutchinson R.J., Sposto R., Weiner M.A., Lones M.A., Perkins S.L., et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704. Ann. Oncol. 13(Suppl 1):2002;107-111
46. Pestalozzi B.C., Sotos G.A., Choyke P.L., Fisherman J.S., Cowan K.H., O'Shaughnessy J.A. Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. Cancer. 71(5):1993;1797-1800
47. Fisherman J.S., Cowan K.H., Noone M., Denicoff A., Berg S., Poplack D., et al. Phase I/II study of 72 h infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J. Clin. Oncol. 14(3):1996;774-782
48. Fisherman JS, McCabe M, Noone M, Ognibene FP, Goldspiel B, Venzon DJ, et al. Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer. J Natl Cancer Inst Monogr 1993;(15):189-94.